ÂÜÀòÂÒÂ×

Michael Yi is currently the Associate Director at CARGO Therapeutics, focusing on research and development to identify strategies to prevent allogeneic rejection of CAR T cells. Prior to this role, Michael held positions at Allogene Therapeutics and PACT Pharma, where Michael demonstrated expertise in generating DNA molecules for high-throughput library generation and optimizing protein expression. Michael's educational background includes a Ph.D. in Chemical Engineering from Stanford University and a Bachelor of Science in Chemical and Biological Engineering from Tufts University.